期刊
MATURITAS
卷 165, 期 -, 页码 52-57出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2022.07.010
关键词
Female sexual dysfunction; cancer survivorship; Menopause; Female sexual health
资金
- Alloy
- Astellas Pharma
- Bayer
- Dare Bioscience
- Lupin Pharmaceuticals, Inc.
- Madorra
- Materna
- Ovoca
- Palatin Technologies, Inc.
- Pfizer Inc.
- Sprout Pharmaceuticals, Inc.
- Strategic Science & Technologies, Therapeutics MD Inc., Ms. Medicine
This narrative review focuses on the impact of cancer treatments on sexual function in female cancer survivors, and discusses the evaluation and management of sexual concerns in this population. Female cancer survivors commonly experience sexual dysfunction, however, it is often underdiagnosed and undertreated. The complex nature of sexual dysfunction after cancer calls for a multidisciplinary approach to care. Validating and addressing sexual health concerns, providing education and appropriate therapies, and timely referral to sexual health experts are crucial in optimizing care for female cancer survivors. Clinicians should be aware of various potential treatment modalities that may contribute to sexual health concerns and individualize management based on contributing factors.
This narrative review examines current evidence regarding sexual function in female cancer survivors, focusing on the impact of cancer treatments as well as the evaluation and management of sexual concerns in this population. Sexual dysfunction in female cancer survivors is prevalent, yet underdiagnosed and undertreated. Many healthcare professionals feel ill-equipped to address the sexual health needs of female cancer survivors. Multiple direct and indirect factors can contribute to sexual dysfunction in female cancer survivors, including effects on the hormonal milieu and physical and sexual well-being. Factors influencing sexual function after cancer may be multifaceted, warranting a multidisciplinary approach to care. Validating and normalizing sexual health concerns and providing education and appropriate therapies, as well as timely referral to appropriate sexual health experts, are key to optimizing cancer survivorship care in women. Clinicians should, at a minimum, be aware of the various potential treatment modalities, taking into account contributing physical, psychological and interpersonal factors. Management of sexual health concerns should be individualized based on contributing factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据